Methods for treating inflammatory conditions or inhibiting JNK

a technology of inflammatory conditions and inhibitors, applied in the direction of antinoxious agents, drug compositions, extracellular fluid disorders, etc., can solve the problems of cell death and scar formation, congestive heart failure, renal failure, or cerebral dysfunction, and selective defect in the ability of th1 effector cells to express ifng

a technology of inflammatory conditions and inhibitors, applied in the direction of antinoxious agents, drug compositions, extracellular fluid disorders, etc., can solve the problems of cell death and scar formation, congestive heart failure, renal failure, or cerebral dysfunction, and selective defect in the ability of th1 effector cells to express ifng

US20040092562A1Inactive Publication Date: 2004-05-13SIGNAL PHARMA LLC
4 Cites 23 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating inflammatory conditions or inhibiting JNK
  • Methods for treating inflammatory conditions or inhibiting JNK
  • Methods for treating inflammatory conditions or inhibiting JNK

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

5.1 DEFINTIONS

[0094] As used herein, the terms used above have the following meaning:

[0095] An "effective amount" when used in connection with a Compound of Formula I-VI, or a pharmaceutically acceptable salt thereof, is an amount effective for treating or preventing an inflammatory condition, a liver disease, a cardiovascular disease, a neurodegenerative disease or cancer.

[0096] A "patient" includes an animal (e.g., cow, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig), in one embodiment a mammal such as a non-primate and a primate (e.g., monkey and human), and in another embodiment a human. In certain embodiments, the patient is an infant, child, adolescent or adult.

[0097] "Alkyl" means a straight chain or branched, saturated or unsaturated chain having from 1 to 8 carbon atoms. Representative saturated alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-me...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperaturesaaaaaaaaaa
temperaturesaaaaaaaaaa
temperaturesaaaaaaaaaa
Login to View More

Abstract

This invention is generally directed to methods for treating or preventing a disease or disorder comprising administering to a patient in need thereof an effective amount of a Jun N-terminal kinase (JNK) inhibitor, such as an isothiazoloanthrone, isoxazoloanthrone, isoindolanthrone, or derivative thereof having the general formula: and pharmaceutically acceptable salts thereof, wherein Ro is -CH2-, -SO-, -O-, -SO2-, or -S-.

Description

[0001] This application is a continuation-in-part of U.S. application Ser. No. 10 / 071,390 filed Feb. 7, 2002 which claims the benefit of U.S. Provisional Application No. 60 / 269,013 filed Feb. 15, 2001, each of which is incorporated by reference herein in its entirety.1. FIELD OF THE INVENTION[0002] This invention is generally directed to methods for treating or preventing a disease or disorder comprising administering to a patient in need thereof an effective amount of a Jun N-terminal kinase ("JNK") inhibitor, such as an isothiazoloanthrone, isoxazoloanthrone, isoindolanthrone, or derivative thereof, including pharmaceutically acceptable salts thereof.2. BACKGROUND OF THE INVENTION[0003] The Jun N-terminal kinase pathway is activated by exposure of cells to environmental stress or by treatment of cells with pro-inflammatory cytokines. Targets of the JNK pathway include the transcription factors c-jun and ATF2 (Whitmarsh A. J., and Davis R. J. J. Mol. Med. 74:589-607, 1996). These t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
13 May 2004
Publication
US20040092562A1
IPC
A61K31/416; A61K31/4439; A61P1/04; A61P1/16; C07D275/06; A61P1/18; A61P7/10; A61P9/00; A61P9/04; A61P9/10; A61P11/00; A61P11/06; A61P13/12; A61P17/02; A61P17/04; A61P17/06; A61P19/00; A61P19/02; A61P19/04; A61P19/06; A61P25/00; A61P25/02; A61P25/08; A61P25/14; A61P25/16; A61P25/28; A61P29/00; A61P35/00; A61P35/02; A61P39/00; A61P43/00; C07D275/04; C07D417/12
CPC
C07D417/12; C07D275/04; A61P1/04; A61P1/16; A61P1/18; A61P11/00; A61P11/06; A61P13/12
Inventors
SAKATA, STEVEN T.; RAYMON, HEATHER K.